Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review

Bruno, Giuseppe; Buccoliero, Giovanni Battista

doi:10.3390/life13101969

Cited by 5 publications

(3 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 In an effort to identify molecules able of inhibiting viral entry or the replication of orthopoxviruses, certain drugs already used for tumor-related conditions, such as imatinib and mitoxantrone, as well as antibiotics like rifampicin have also been suggested. 29 Drug repurposing, 30 computational approaches, 31 and artificial intelligence 32 have also been used to suggest new therapeutic options for MPXV infection.…”

Section: Mpxv Virus From Deceased Patientsmentioning

confidence: 99%

Molecular and phylogenetic characterization of the monkeypox outbreak in the South of Spain

Casimiro‐Soriguer,

Perez‐Florido,

Lara

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimUntil the May 2022 Monkeypox (MPXV) outbreak, which spread rapidly to many non‐endemic countries, the virus was considered a viral zoonosis limited to some African countries. The Andalusian circuit of genomic surveillance was rapidly applied to characterize the MPXV outbreak in the South of Spain.MethodsWhole genome sequencing was used to obtain the genomic profiles of samples collected across the south of Spain, representative of all the provinces of Andalusia. Phylogenetic analysis was used to study the relationship of the isolates and the available sequences of the 2022 outbreak.ResultsWhole genome sequencing of a total of 160 MPXV viruses from the different provinces that reported cases were obtained. Interestingly, we report the sequences of MPXV viruses obtained from two patients who died. While one of the isolates bore no noteworthy mutations that explain a potential heightened virulence, in another patient the second consecutive genome sequence, performed after the administration of tecovirimat, uncovered a mutation within the A0A7H0DN30 gene, known to be a prime target for tecovirimat in its Vaccinia counterpart. In general, a low number of mutations were observed in the sequences reported, which were very similar to the reference of the 2022 outbreak (OX044336), as expected from a DNA virus. The samples likely correspond to several introductions of the circulating MPXV viruses from the last outbreak. The virus sequenced from one of the two patients that died presented a mutation in a gene that bears potential connections to drug resistance. This mutation was absent in the initial sequencing before treatment.

show abstract

Section: Mpxv Virus From Deceased Patientsmentioning

confidence: 99%

Molecular and phylogenetic characterization of the monkeypox outbreak in the South of Spain

Casimiro‐Soriguer,

Perez‐Florido,

Lara

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…25 Due to the sudden rise of mpox infection in recent years, some therapeutic approaches have been fully or partially approved under some restrictions and guidance for treatment purposes. 26 Moreover, these measures aim to offer patients effective treatment options considering the condition and progression of infection in the patient. 27…”

Section: Epidemiology Of Recent Outbreakmentioning

confidence: 99%

Prediction of potential public health risk of the recent multicountry monkeypox outbreak: An update after the end declaration of global public health emergency

Haque,

Halder,

Hossain

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsA double‐stranded DNA virus called monkeypox virus (MPV) belonging to the Poxviridae family and Orthopoxvirus genus causes monkeypox (mpox) infection. This virus used to infect only Central, East, and West Africa. However, it has spread to an extent outside Africa recently. The range of MPV outbreaks was so high that on July 23, 2022, the World Health Organization (WHO) declared it a Public Health Emergency of International Concern (PHEIC). About a year later, the WHO notified the end of a global public health emergency for mpox on May 11, 2023. Here, we aimed to assess the current pathogenicity and potential risk of MPV causing public health emergencies.MethodsWe searched information from published articles available in PubMed, Scopus, and ScienceDirect. We used monkeypox, mpox, monkeypox outbreak, and monkeypox virus as keywords during the literature search.ResultsMany new variants of MPV have emerged throughout the world that created PHEIC for mpox. Considering the low lethality and transmission rate, mpox is no longer a global public health threat. In addition, the availability of therapeutic and preventive measures helped the healthcare authorities fight the mpox infection in an efficient manner. In this review, we have portrayed the history and evolution of mpox from past to present and an idea of its future outcomes. Also, we have discussed the symptoms related to mpox and approved antiviral treatment strategies to fight off the infection in this piece. This review also emphasized the preventive guidelines set by the WHO for patients, caregivers, and healthcare providers to control the outbreak of mpox infection.ConclusionWe believe this article would give an idea about the potential public health threats of the recent multi‐country monkeypox outbreak to the healthcare authorities for taking measures accordingly.

show abstract

“…Tecovirimat blocks the p37 protein, while cidofovir and brincidofovir interfere with the virus's DNA synthesis. Cidofovir is an antiviral prodrug, which means it must first be converted into its active form by the body [88]. Brincidofovir is a more effective form of cidofovir.…”

Section: Management Of Mpox Infectionmentioning

confidence: 99%

Mapping the Landscape of Health Research Priorities for Effective Pandemic Preparedness in Human Mpox Virus Disease

Aggarwal,

Agarwal,

Nigam

et al. 2023

Pathogens

View full text Add to dashboard Cite

The global re-emergence of monkeypox (Mpox) in non-endemic regions in 2022 has highlighted the critical importance of timely virus detection and robust public health surveillance in assessing outbreaks and their impact. Despite significant Mpox research being conducted worldwide, there is an urgent need to identify knowledge gaps and prioritize key research areas in order to create a roadmap that maximizes the utilization of available resources. The present research article provides a comprehensive mapping of health research priorities aimed at advancing our understanding of Mpox and developing effective interventions for managing its outbreaks, and, as evidenced by the fact that achieving this objective requires close interdisciplinary collaboration. The key research priorities observed were identifying variants responsible for outbreaks; discovering novel biomarkers for diagnostics; establishing suitable animal models; investigating reservoirs and transmission routes; promoting the One Health approach; identifying targets for vaccination; gaining insight into the attitudes, experiences, and practices of key communities, including stigma; and ensuring equity during public health emergencies. The findings of this study hold significant implications for decision making by multilateral partners, including research funders, public health practitioners, policy makers, clinicians, and civil society, which will facilitate the development of a comprehensive plan not only for Mpox but also for other similar life-threatening viral infections.

show abstract

Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review

Cited by 5 publications

References 90 publications

Molecular and phylogenetic characterization of the monkeypox outbreak in the South of Spain

Molecular and phylogenetic characterization of the monkeypox outbreak in the South of Spain

Prediction of potential public health risk of the recent multicountry monkeypox outbreak: An update after the end declaration of global public health emergency

Mapping the Landscape of Health Research Priorities for Effective Pandemic Preparedness in Human Mpox Virus Disease

Contact Info

Product

Resources

About